Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Long-Term Results of a Prospective Phase II Study

The optimal therapy for patients with non-metastatic biochemically relapsed prostate cancer (BRPC-M0) after local is elusive. Thus, the evaluation of new non-toxic compounds in BRPC-M0 warranted. PectaSol®-Modified citrus pectin (P-MCP) a food supplement categorized as GRAS (Generally Recognized As Safe) by FDA. It competitive inhibitor galectin-3 protein, which involved pathogenesis. In an early report present phase 2 study, P-MCP treatment 6 months led to prostate-specific antigen doubling time (PSADT) improvement 75% BRPC-M0. Herein, we second long-term additional 12 (4.8 g × 3/day orally) without disease progression initial therapy. Of 46 that entered phase, 7 withdrew consent and decided continue out pocket, 39 initiated phase. After total 18 treatment, 85% (n = 33) had durable response, 62% 24) showing decreased/stable PSA, 90% 35) PSADT improvement, all negative scans. No patient grade 3/4 toxicity. conclusion, may have efficacy safe